LRP6 is a Wnt co-receptor (Thompson and Monga, 2007; Tamai et al., 2000) and is linked to metabolic diseases in humans since several loss-of-function mutations within LRP6 were shown to cause hypertriglyceridemia (Go, 2015; Mani et al., 2007), hypercholesterinemia (Liu et al., 2011; Ye et al., 2012), NAFLD (Go et al., 2014) and atherosclerosis (Mani et al., 2007; Keramati et al., 2011). Here, LRP6 is linked to metabolic dysfunction-associated steatotic liver disease.